OncoTrack MRD Test
(Molecular Residual Disease)

What is OncoTrack MRD?

MedGenome’s OncoTrack MRD is a tumor-informed, minimally-invasive, ultra-sensitive test which can monitor treatment response, guide treatment decisions and detect recurrence (surveillance) before it becomes clinically evident.

Book a Test Now

OncoTrack MRD monitors the cancer’s molecular fingerprint across the patient’s journey

Key Features of MedGenome’s OncoTrack MRD

Feature Description
Tumor-informed Ultra-sensitive, personalised, tumor “fingerprint”, is designed with ~50-100 mutations.
Quantitative measurement Using this tumor “fingerprint”, the MRD status is interpreted post-treatment and during follow-up.
Ultra-low detection This test has been validated down to 50 parts per million (PPM) analytical sensitivity

Clinical Application of OncoTrack MRD

  • Get direct molecular insight into the tumor’s response to neoadjuvant/adjuvant treatment.
  • Escalate/de-escalate ongoing treatment based on the MRD status.
  • Detect molecular relapse far before it becomes evident in imaging.

Specifications

  • Indications: All solid tumors (for e.g. colorectal cancer, lung cancer, ovarian cancer, etc.)
  • Methodology: Whole-exome sequencing at baseline and ultra-deep sequencing of ctDNA.
  • Sample Type: FFPE tissue blocks and peripheral blood in streck tube at baseline and, subsequently, only peripheral blood during follow-up.
  • Findings: Current and historical ctDNA levels are provided in PPM.

With OncoTrack MRD, stay ahead of the tumor and treat it effectively

MRD Tests Offered by MedGenome

OncoTrack MRD (Tumor-Informed – Baseline)

  • Sample: FFPE tissue block (minimum 25% tumor content) and Blood in streck tube (2 x 10 ml)

  • TAT: 35 Working Days

  • Test Code - MGM3697

OncoTrack MRD (Tumor-Informed - Surveillance)

  • Sample: Blood in streck tube (2 x 10 ml)

  • TAT: 14 Working Days

  • Test Code - MGM3698

Key Highlights of Molecular Testing in MRD Testing

Personalised, tumor-informed

ctDNA based MRD

Ultra-low detection

(down to 50 PPM)

Monitoring

Assess, guide and monitor the effectiveness of treatment

What is Molecular Residual Disease (MRD)?

After cancer treatment, a very small number of cancer cells may remain in the body. These cells may be too few to be detected through routine tests or under a microscope. This is called Molecular Residual Disease (MRD).
Even a small number of remaining cancer cells may increase the risk of the disease returning if not monitored carefully.

Book a Test Now
MedGenome scientist conducting genetic testing and DNA test services in India

Why is MRD Testing Important?

MRD testing helps doctors:

  • Understand how well treatment is working.
  • Detect early signs of disease recurrence.
  • Assess the risk of relapse.
  • Guide treatment and follow-up decisions.

An MRD-negative result generally indicates a deeper treatment response, while an MRD-positive result may require closer monitoring or additional treatment evaluation.

How is Tumor-informed MRD Testing Performed?

Who May Benefit from MRD Testing?

MedGenome clinician reviewing patient records to support genetic testing and DNA test in India

When is MRD Testing Recommended?

MRD testing may be advised:

  • Before the start of neoadjuvant treatment.
  • Before and after surgery.
  • During adjuvant chemotherapy/radiotherapy.
  • For long-term monitoring, even after the cancer has been treated.

The timing of testing depends on the type of cancer and treatment plan.

What Do MRD Results Mean?

FAQs

  • How often should MRD testing be done?

    The frequency of MRD testing depends on the type of cancer, treatment plan, and clinical condition of the patient. MRD assessment is commonly performed before the start of neoadjuvant chemotherapy, before and after surgery, during post-surgery treatment and for long-term follow-up monitoring. Your oncologist will determine the appropriate testing schedule based on disease-specific guidelines and treatment response.

  • Which cancers require MRD testing?

    Tumor-informed MRD testing is used in solid tumors, most often in colorectal cancer, lung cancer, breast cancer and bladder cancer. This ctDNA-based approach is used to assess treatment response and detect molecular relapse.

  • Can MRD predict relapse?

    Yes. MRD positivity may indicate the presence of residual cancer cells that remain after treatment and can increase the risk of disease relapse. In many cancers, MRD detection can identify molecular relapse weeks to months before clinical symptoms appear or conventional diagnostic methods detect recurrence, enabling earlier clinical intervention and personalized treatment decisions.

Get Genetic Counselling by Our Experts

Connect with Our Experts

    MedGenome Patient Stories

    Please share your details to get
    in touch with our experts.

      At MedGenome, scientific experts drive the development of innovative omics solutions that enable early detection of complex diseases. With advanced global-quality next-generation sequencing and proprietary analysis pipelines, the team consistently delivers tests and services that are transforming the way diseases are diagnosed and treated.

      Business Hours: 9 AM - 6 PM
      Toll-Free Hours: 9 AM - 7 PM

      MedGenome Labs Ltd.

      Sy. Nos. 94/1C and 94/2, Tower 1, Ground Floor, Veerasandra Village, Attibele Hobli, Electronic City Phase-1, Electronics City, Bangalore, Bangalore South, Karnataka, India, 560100 Toll free number: 1800 296 9696

      Accreditations

      *Explore our range of CAP-accredited tests- Click to know more

      Quick Links
      Tests & Services
      Resources